An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

NCT04155190 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

47

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated early due to low blinded event rate

Conditions

Recurrent Basal Cell Carcinoma

Interventions

DRUG: Patidegib Topical Gel, 2%
DRUG: Patidegib Topical Gel, Vehicle

Sponsor

Sol-Gel Technologies, Ltd.